Abstract:Background: Primary Sjogren syndrome (pSS) is a chronic autoimmune disorder affecting 0.2–3% of the population. However, there are currently no effective systemic therapies. Anti-Ro, anti-La and rheumatoid factor(RF) as well as hyper γ-globulinaemia indicate a degree of B cell hyperactivity. In the recent ten years, iguratimod (T-614) has been used to treat RA as a novel immunomodulatory, which functions by suppressing the production of some inflammatory cytokines, as well as reducing immunoglobulin production by acting directly on human B lymphocytes without affecting B lymphocyte proliferation. Objectives: We evaluated the effectiveness and safety of iguratimod on pSS patients in this follow up study. Methods: A total of 21 pSS patients without severe systemic damage needing corticosteroid were recruited to receive iguratimod 25mg Bid for 12 weeks. Results: Among them, 1 patient and 2 patients withdrew because of kidney dysfunction and ineffectiveness. For those 18 patients who finished the follow up, 94.4% were females and average age were 46.5±13.8 year-old with median disease duration of 22.0 (9.8, 58.5) months. Compared with baseline, ESSDAI score, hyperglobulinaemia and ESR was significant decreased after iguratimod treatment (Table). Two of the 18 patients presented with decreased white blood cell count. This side effect ameliorated in one patient after tapering the dose to 25mg Qd and in another patient after 2 weeks without any intervention. Table. Effectiveness of iguratimod in pSS Baseline (B) 12w P value(vs. B) 24w P value(vs.12W) P value(vs. B) IgG 23.19±5.50 20.19±5.21 0.009 18.52±4.64 0.064 0.001 IgM 1.27±0.39 0.98±0.42 0.000 0.97±0.39 0.908 0.001 IgA 4.16±1.30 3.51±1.41 0.000 3.29±1.07 0.045 0.000 ESR 26.69±17.68 19.62±10.89 0.015 15.57±11.28 0.929 0.043 ESSDAI 4.5±2.5 3.0±2.4 0.001 2.08±1.44 0.237 0.004 Conclusion: This is the first follow study of iguratimod in pSS to show benefit with good tolerance. References [1] Saraux, A., et al. (2016). “Treatment of primary Sjogren syndrome.” Nat Rev Rheumatol 12(8): 456-471. [2] Li, J., et al. (2013). “Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.” Clin Dev Immunol 2013: 310628. [3] Ramos-Casals, M., et al. (2010). “Treatment of primary Sjogren syndrome: a systematic review.” JAMA 304(4): 452-460. Disclosure of Interests: Hui Gao Grant/research support from: This work was supported by grant from PANDA (Z-2014-06-2-1637)., Xiao-ying Zhang: None declared, Xue-wu Zhang: None declared, Zhanguo Li: None declared

Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease

Mycophenolate for the Treatment of Primary Sjögren's Syndrome.

Interstitial Lung Disease in Primary Sjögren's Syndrome: Risk factors for occurrence and radiographic progression

Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: A systematic review from the Italian Society of Rheumatology

AB0373 Treatment of Primary Sjogren’s Syndrome-Associated Lung Disease: a Prospective Study

Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis

Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome

Associated Factors with Interstitial Lung Disease and Health-Related Quality of Life in Chinese Patients with Primary Sjögren’s Syndrome

Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results

Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment

Clinical features and risk factors for primary Sjögren’s syndrome combined with interstitial lung disease: a retrospective study

AB0465 EFFICACY AND SAFETY OF IGURATIMOD IN PATIENTS WITH PRIMARY SJOGREN SYNDROME: A FOLLOW-UP STUDY

Characteristics and Mortality in Primary Sjögren Syndrome–related Interstitial Lung Disease

Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis

Tofacitinib in the treatment of primary Sjögren's syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial

Clinical analysis of primary Sjogren's syndrome with interstitial lung disease

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: A case-control study.

The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients